General

M42’s Diaverum Expands with UAE Market Entry to Provide Critical Renal Care


Abu Dhabi: Diaverum, a global leader in renal care acquired by M42 in 2023, has announced plans to start operations in Abu Dhabi and Al Ain, bringing advanced technological solutions and personalised patient care to renal patients in the UAE.



According to Emirates News Agency, as the largest provider of renal care in the Kingdom of Saudi Arabia with 40 clinics in 33 cities and 1,300 healthcare professionals, Diaverum is expanding its footprint in the Gulf region with its UAE plans to deliver a variety of treatment options, including hemodialysis, holiday dialysis, and home dialysis. The company aims to prioritise preventive care and education initiatives to tackle the rising burden of chronic kidney disease (CKD).



Additionally, Diaverum will leverage M42’s Global Patient Care platform, along with its digital and integrated healthcare capabilities, to disrupt traditional renal care models and shift towards precision and preventive approaches for longer, healthier lives. This commitment will be reflected in collaborations with M42’s Imperial College London Diabetes Centre (ICLDC) to help tackle diabetes, a leading cause of CKD.



Commenting on the expansion, Ziyad Kabli, Chief Operating Officer for Diaverum Middle East and Africa, stated that their entry into the UAE marks a significant step forward in their mission to transform renal care globally and expand their reach in the Middle East. The region faces increasing healthcare challenges related to chronic kidney diseases for patients, communities, and healthcare systems. By combining their high standards of care and expertise in AI-driven, personalised renal treatment with M42’s comprehensive patient care platform and local presence, Diaverum aims to shape a future-focused renal care landscape in the UAE.



Dr. Ali Anees, Chief Operating Officer for Global Patient Care in the UAE and Bahrain, added that Diaverum’s entry into the UAE highlights M42’s commitment to delivering world-class care for renal patients. This expansion is part of their plan to disrupt traditional healthcare models and positively impact lives locally and globally. M42 plans to use its knowledge and expertise in AI, genomics, and tech-powered solutions to advance Diaverum’s ability to deliver precise, life-saving renal care.



Dimitris Moulavasilis, Chief Executive Officer of Diaverum, mentioned that as the demand for specialised renal care in the UAE grows, Diaverum’s market entry is on familiar grounds due to its association with M42. The company is committed to serving the people in the country and region by establishing a resilient, patient-centric, and AI-enabled renal care provision ecosystem to deliver unparalleled levels of personalised care to CKD patients.



Chronic kidney disease (CKD) is an escalating global health challenge, affecting approximately 10 percent of the world’s population and is projected to be the fifth leading cause of death by 2040. This represents a particular challenge in the UAE, where 16.4 percent of adults suffer from diabetes, a leading cause of kidney failure. The country also faces challenges related to lifestyle factors such as obesity, which can contribute to the rise in CKD.



Diaverum operates with 13,500 healthcare professionals spread across 450 clinics in 24 countries, offering life-enhancing renal care to patients. Diaverum’s primary mission is to improve the quality of life for patients with chronic kidney disease (CKD) by providing personalised care that empowers them to live fulfilling lives through its proprietary Care Delivery Model, supported by a continuously evolving digital infrastructure and underscored by its True Care culture.

Related Articles

Back to top button